Westlake Village drug developer GT Biopharma announced a collaboration with the U.S.-based subsidiary of a Chinese company to produce and test its TriKE therapeutic platform to treat patients infected with the novel coronavirus. Cytovance Biologics, a subsidiary of Shenzhen Hepalink Pharmaceutical, will manufacture GT Biopharma’s drug for preclinical evaluation and could later scale up production…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
